Clinical trial
Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer…
NCT00003622 · James Ahlgren, Other · Withdrawn
Key facts
| NCT number | NCT00003622 |
|---|---|
| Title | Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy |
| Official title | Phase II Study of Vinorelbine With Paclitaxel in the Treatment of Hormone-Refractory Prostate Cancer |
| Lead sponsor | James Ahlgren, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | paclitaxel, vinorelbine tartrate |
| Enrollment | 0 |
| Start date | Jan 1, 1999 |
| Primary completion | May 1, 2008 |
| Completion | Feb 22, 2017 |
| First posted | May 3, 2004 |
| Last update posted | Jul 13, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: